GH Research (GHRS) Competitors $13.84 +0.21 (+1.54%) Closing price 04:00 PM EasternExtended Trading$13.72 -0.12 (-0.87%) As of 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GHRS vs. IMVT, GMTX, CPRX, ALVO, KNSA, OGN, TARS, CNTA, DNLI, and AGIOShould you be buying GH Research stock or one of its competitors? The main competitors of GH Research include Immunovant (IMVT), Gemini Therapeutics (GMTX), Catalyst Pharmaceuticals (CPRX), Alvotech (ALVO), Kiniksa Pharmaceuticals International (KNSA), Organon & Co. (OGN), Tarsus Pharmaceuticals (TARS), Centessa Pharmaceuticals (CNTA), Denali Therapeutics (DNLI), and Agios Pharmaceuticals (AGIO). These companies are all part of the "pharmaceutical products" industry. GH Research vs. Its Competitors Immunovant Gemini Therapeutics Catalyst Pharmaceuticals Alvotech Kiniksa Pharmaceuticals International Organon & Co. Tarsus Pharmaceuticals Centessa Pharmaceuticals Denali Therapeutics Agios Pharmaceuticals Immunovant (NASDAQ:IMVT) and GH Research (NASDAQ:GHRS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment. Do analysts rate IMVT or GHRS? Immunovant presently has a consensus price target of $35.20, indicating a potential upside of 137.52%. GH Research has a consensus price target of $32.00, indicating a potential upside of 131.21%. Given Immunovant's higher probable upside, analysts plainly believe Immunovant is more favorable than GH Research.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunovant 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.83GH Research 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88 Is IMVT or GHRS more profitable? GH Research's return on equity of -16.71% beat Immunovant's return on equity.Company Net Margins Return on Equity Return on Assets ImmunovantN/A -80.99% -72.23% GH Research N/A -16.71%-16.06% Do insiders and institutionals have more ownership in IMVT or GHRS? 47.1% of Immunovant shares are owned by institutional investors. Comparatively, 56.9% of GH Research shares are owned by institutional investors. 1.8% of Immunovant shares are owned by insiders. Comparatively, 41.6% of GH Research shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has stronger earnings and valuation, IMVT or GHRS? GH Research is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunovantN/AN/A-$413.84M-$2.85-5.20GH ResearchN/AN/A-$38.96M-$0.74-18.70 Which has more volatility and risk, IMVT or GHRS? Immunovant has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Comparatively, GH Research has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Does the media refer more to IMVT or GHRS? In the previous week, Immunovant had 8 more articles in the media than GH Research. MarketBeat recorded 10 mentions for Immunovant and 2 mentions for GH Research. Immunovant's average media sentiment score of 1.38 beat GH Research's score of 0.93 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GH Research 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryGH Research beats Immunovant on 8 of the 14 factors compared between the two stocks. Get GH Research News Delivered to You Automatically Sign up to receive the latest news and ratings for GHRS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GHRS vs. The Competition Export to ExcelMetricGH ResearchMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$709.14M$3.10B$5.78B$9.80BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-18.7021.0831.2626.59Price / SalesN/A400.78464.64173.43Price / CashN/A44.6737.7359.36Price / Book2.378.0910.046.68Net Income-$38.96M-$54.08M$3.27B$265.59M7 Day Performance6.54%2.25%3.17%3.42%1 Month Performance-7.61%3.41%4.34%1.09%1 Year Performance25.82%18.61%44.12%23.84% GH Research Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GHRSGH Research2.2909 of 5 stars$13.84+1.5%$32.00+131.2%+20.4%$709.14MN/A-18.7010Positive NewsUpcoming EarningsIMVTImmunovant3.0194 of 5 stars$14.89-2.3%$35.20+136.4%-52.1%$2.66BN/A-5.22120News CoveragePositive NewsGMTXGemini TherapeuticsN/A$60.35+1.0%N/A+20.2%$2.61BN/A-60.3530News CoverageCPRXCatalyst Pharmaceuticals4.8524 of 5 stars$20.62-2.2%$33.20+61.0%-1.4%$2.58B$491.73M12.5080Insider TradeALVOAlvotech2.0116 of 5 stars$8.32-1.5%$14.00+68.3%-31.5%$2.55B$491.98M36.171,032KNSAKiniksa Pharmaceuticals International2.4181 of 5 stars$33.04-2.1%$41.17+24.6%+24.5%$2.50B$423.24M826.21220OGNOrganon & Co.4.8006 of 5 stars$9.08-3.8%$18.00+98.3%-58.9%$2.45B$6.40B3.374,000Positive NewsTARSTarsus Pharmaceuticals1.8276 of 5 stars$56.61-1.1%$66.67+17.8%+114.2%$2.42B$182.95M-24.3050Positive NewsCNTACentessa Pharmaceuticals2.4804 of 5 stars$17.00-0.1%$28.10+65.3%+23.3%$2.28B$6.85M-9.50200DNLIDenali Therapeutics4.318 of 5 stars$15.57+0.5%$33.62+115.9%-37.5%$2.26B$330.53M-5.56430Positive NewsAGIOAgios Pharmaceuticals4.3635 of 5 stars$37.26-4.0%$56.33+51.2%-16.6%$2.25B$36.50M3.39390Positive News Related Companies and Tools Related Companies Immunovant Alternatives Gemini Therapeutics Alternatives Catalyst Pharmaceuticals Alternatives Alvotech Alternatives Kiniksa Pharmaceuticals International Alternatives Organon & Co. Alternatives Tarsus Pharmaceuticals Alternatives Centessa Pharmaceuticals Alternatives Denali Therapeutics Alternatives Agios Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GHRS) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GH Research PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share GH Research With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access